STOCK TITAN

CytomX Therapeutics, Inc. - CTMX STOCK NEWS

Welcome to our dedicated news page for CytomX Therapeutics (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CytomX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CytomX Therapeutics's position in the market.

Rhea-AI Summary
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline. The company is well-positioned with multiple IND applications filed and a broad pipeline progress anticipated within research and development partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
none
-
Rhea-AI Summary
CytomX Therapeutics, Inc. (Nasdaq: CTMX) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
conferences
-
Rhea-AI Summary
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported third quarter 2023 financial results and provided a business update, including the progress of CX-904, CX-2051, and CX-801, with anticipated milestones for 2024. The company's cash, cash equivalents, and investments totaled $194.1 million as of September 30, 2023, with a total revenue of $26.4 million for the three months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
Rhea-AI Summary
CytomX Therapeutics, Inc. announced its participation in three investor conferences in November. The conferences include BMO Biopharma Spotlight Series: Oncology Day on November 8th, Jefferies London Healthcare Conference on November 16th, and Piper Sandler Healthcare Conference on November 29th. The company will be conducting fireside chats and live webcasts of the Jefferies London and Piper Sandler conferences will be available on CytomX's website. Management will also be available for one-on-one meetings with registered investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
conferences
-
Rhea-AI Summary
CytomX Therapeutics, Inc. will report its third quarter financial results on November 7, 2023, after the close of U.S. markets. The company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the live webcast and register for the conference call on CytomX's website. An archived replay of the webcast will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
conferences earnings
-
Rhea-AI Summary
CytomX Therapeutics, Inc. announced that preclinical data supporting its conditionally activated cytokine program, CX-801, will be presented at the Society for Immunotherapy of Cancer Annual Meeting. The IND filing for CX-801 is expected by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
conferences clinical trial
Rhea-AI Summary
CytomX Therapeutics presents preclinical data on EpCAM-targeting ADC, CX-2051
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CytomX Therapeutics to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
Rhea-AI Summary
CytomX Therapeutics, Inc. (CTMX) reported Q2 2023 financial results and business update. They strengthened their financial position with a strategic financing, extended cash runway, and advanced their Probody Therapeutic pipeline. They anticipate multiple clinical milestones for key pipeline programs over the next 12 to 18 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
CytomX Therapeutics, Inc.

Nasdaq:CTMX

CTMX Rankings

CTMX Stock Data

110.40M
53.82M
1.19%
48.6%
4.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About CTMX

cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o